PortfoliosLab logo
AIM ImmunoTech Inc. (AIM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00901B1052

CUSIP

00901B105

IPO Date

Jul 12, 1996

Highlights

Market Cap

$6.52M

EPS (TTM)

-$0.31

Total Revenue (TTM)

$130.00K

Gross Profit (TTM)

$107.00K

EBITDA (TTM)

-$10.80M

Year Range

$0.06 - $0.47

Target Price

$2.75

Short %

5.01%

Short Ratio

3.10

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


AIM

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

1.30%

1M

12.94%

6M

1.49%

1Y

12.48%

5Y*

15.82%

10Y*

10.87%

*Annualized

Monthly Returns

The table below presents the monthly returns of AIM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20251.97%-33.14%-9.41%-22.40%-52.07%
2024-5.68%-3.61%17.75%-13.27%-11.38%2.96%-3.43%-4.61%-21.35%-3.74%-11.47%-13.95%-55.00%
202367.74%-0.00%-17.31%11.63%-4.17%45.65%-7.46%-0.00%-25.81%0.00%2.17%-6.38%41.94%
2022-8.70%-15.48%49.30%-0.94%-13.33%-14.29%-6.41%-8.22%-13.43%-1.72%-28.07%-24.39%-66.30%
202113.41%11.33%0.44%-4.85%-4.63%4.37%-2.79%-1.44%-1.94%-11.39%-17.88%-37.41%-48.60%
202085.19%105.00%24.88%-18.75%34.62%-11.43%17.74%-22.95%-4.44%-3.72%-11.11%-2.72%231.48%
201927.78%-21.74%-11.11%31.25%-52.38%-0.23%-46.47%-23.40%-57.78%-34.21%-20.00%35.00%-93.18%
201842.86%-0.00%-20.00%-20.00%0.00%0.00%-9.38%-3.45%-17.86%0.00%-21.74%0.00%-48.57%
20170.00%-30.43%14.58%21.82%-11.94%-15.25%-16.00%-14.29%-11.11%-3.12%3.23%9.38%-49.28%
201612.50%55.56%-7.14%7.69%-14.29%-0.00%8.33%-6.41%-13.70%-22.22%-16.33%-15.85%-28.13%
2015-12.00%9.09%-4.17%13.04%-11.54%-13.04%-0.00%-10.00%-5.56%-23.53%-7.69%-33.33%-68.00%
201462.96%-9.09%0.00%-17.50%0.00%-6.06%-9.68%-3.57%18.52%-9.38%-10.34%-3.85%-7.41%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AIM is 6, meaning it’s performing worse than 94% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AIM is 66
Overall Rank
The Sharpe Ratio Rank of AIM is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of AIM is 33
Sortino Ratio Rank
The Omega Ratio Rank of AIM is 55
Omega Ratio Rank
The Calmar Ratio Rank of AIM is 55
Calmar Ratio Rank
The Martin Ratio Rank of AIM is 1010
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AIM ImmunoTech Inc. (AIM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for AIM ImmunoTech Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


AIM ImmunoTech Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the AIM ImmunoTech Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AIM ImmunoTech Inc. was 100.00%, occurring on Apr 4, 2025. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Mar 10, 20006306Apr 4, 2025
-61%Sep 10, 1998110Feb 17, 1999258Feb 24, 2000368
-58%Oct 14, 199674Jan 28, 1997167Sep 25, 1997241
-48.84%Nov 21, 199794Apr 8, 199865Jul 13, 1998159
-40.91%Jul 16, 199619Aug 9, 19965Aug 16, 199624

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AIM ImmunoTech Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of AIM ImmunoTech Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -11.1%.


-0.30-0.25-0.20-0.15-0.10-0.05AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.10
-0.09
Actual
Estimate

Valuation

The Valuation section provides an overview of how AIM ImmunoTech Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AIM relative to other companies in the Biotechnology industry. Currently, AIM has a P/S ratio of 38.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AIM in comparison with other companies in the Biotechnology industry. Currently, AIM has a P/B value of 2.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items